Finance

Lists
EW:NYSE
Edwards Lifesciences Corp
$ 86.29
+0.65%
(+0.56) 1D
$ 85.50
-0.92% (-0.79)
After hours
Closed: 9-р сарын 25, 16:00:06 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EW...
Open
$ 86.66
High
$ 87.11
Low
$ 84.92
Mkt. cap
49.74 тэрбум
Avg. vol.
3.10 сая
Volume
3.60 сая
P/E ratio
49.92
52-wk high
$ 96.29
52-wk low
$ 72.30
EPS
$ 1.73
Beta
0.85
Shares outstanding
576.40 сая
No. of employees
16 мян
Open
$ 86.66
High
$ 87.11
Low
$ 84.92
Mkt. cap
49.74 тэрбум
Avg. vol.
3.10 сая
Volume
3.60 сая
P/E ratio
49.92
52-wk high
$ 96.29
52-wk low
$ 72.30
EPS
$ 1.73
Beta
0.85
Shares outstanding
576.40 сая
No. of employees
16 мян
Profile
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027. Wikipedia
About Edwards Lifesciences Corp
CEO-
Employees16 мян
Founded1958
HeadquartersИрвин, Калифорни, Америкийн Нэгдсэн Улс
Sector-
Analyst ratings
Based on 17 analysts giving stock ratings to EW in the past 3 months
Strong buy
Buy
14
Hold
3
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for EW in the last 3 months.
Highest
Current $ 86.29
$ 110.00 (+27.48%)
Average
$ 103.40 (+19.83%)
Lowest
$ 85.00 (-1.49%)
Analyst
Recommendation
Action
Price target
Projected
Date
Adam Maeder
Piper Sandler
Buy
Maintained
$ 101.00
+17%
09/21/2026
Matthew Taylor
Jefferies
Buy
Maintained
$ 105.00
+21.7%
09/11/2026
Marie Thibault
BTIG
Buy
Maintained
$ 110.00
+27.5%
09/10/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
09/10/2026
Joanne Wuensch
Citi
Buy
Maintained
$ 110.00
+27.5%
09/10/2026
William Plovanic
Canaccord Genuity
Hold
Maintained
$ 85.00
-1.5%
08/03/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
$ 105.00
+21.7%
07/28/2026
Patrick Wood
UBS
Buy
Upgraded
$ 110.00
+27.5%
07/28/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
$ 110.00
+27.5%
07/24/2026
Suraj Kalia
Oppenheimer
Hold
Maintained
-
-
07/24/2026
Richard Newitter
Truist Financial
Hold
Reiterated
$ 95.00
+10.1%
07/24/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
$ 110.00
+27.5%
07/23/2026
Mike Kratky
Leerink Partners
Buy
Upgraded
$ 101.00
+17%
07/24/2026
Travis Steed
Bank of America Securities
Buy
Maintained
$ 100.00
+15.9%
07/21/2026
Josh Jennings
TD Cowen
Buy
Reiterated
$ 104.00
+20.5%
07/23/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
$ 105.00
+21.7%
07/15/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$ 100.00
+15.9%
07/06/2026
David Roman
Goldman Sachs
Buy
Maintained
$ 98.00
+13.6%
06/15/2026
Krish Sankar
TD Cowen
Buy
Reiterated
$ 104.00
+20.5%
06/02/2026
David Toung
Argus Research
Buy
Maintained
-
-
05/21/2026
David Rescott
Robert W. Baird
Hold
Maintained
$ 87.00
+0.8%
04/24/2026
Matt Miksic
Barclays
Buy
Maintained
$ 110.00
+27.5%
04/24/2026
Michael Polark
Wolfe Research
Buy
Upgraded
$ 92.00
+6.6%
04/01/2026
Danielle Antalffy
UBS
Hold
Maintained
$ 90.00
+4.3%
02/12/2026
Larry Biegelsen
Wells Fargo
Buy
Reiterated
$ 100.00
+15.9%
02/11/2026
Last report
2026 оны 7-р сарын 23
Fiscal period
Q2 2026
EPS / Est. (USD)
$ 0.78 / $ 0.74
+5.11%beat
Revenue / Est. (USD)
1.74 тэрбум / 1.70 тэрбум
+2.44%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
1.55 тэрбум
1.57 тэрбум
1.65 тэрбум
1.74 тэрбум
Cost of goods sold
345.20 сая
343.00 сая
362.60 сая
392.40 сая
Cost of revenue
345.20 сая
343.00 сая
362.60 сая
392.40 сая
Research and development expenses
280.70 сая
267.70 сая
263.30 сая
278.90 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
514.60 сая
601.20 сая
522.20 сая
561.20 сая
Operating expense
782.80 сая
854.60 сая
771.30 сая
829.10 сая
Total operating expenses
1.13 тэрбум
1.20 тэрбум
1.13 тэрбум
1.22 тэрбум
Operating income
425.10 сая
372.00 сая
514.70 сая
519.50 сая
Other non operating income
1.10 сая
2.30 сая
69.90 сая
-25.00 сая
EBT including unusual items
348.40 сая
90.40 сая
459.00 сая
519.80 сая
EBT excluding unusual items
444.50 сая
464.00 сая
603.60 сая
511.10 сая
Income tax expense
56.10 сая
26.20 сая
78.30 сая
278.40 сая
Effective tax rate
16.10%
28.98%
17.06%
53.56%
Other operating expenses
-12.50 сая
-14.30 сая
-14.20 сая
-11.00 сая
Net income
291.10 сая
91.20 сая
380.70 сая
241.90 сая
Net profit margin
18.74%
5.81%
23.09%
13.89%
Earnings per share
0.67
0.58
0.78
0.78
Interest and investment income
16.70 сая
114.20 сая
17.40 сая
15.00 сая
Interest expense
-
-20.40 сая
-
-
Net interest expenses
16.70 сая
93.80 сая
17.40 сая
15.00 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
464.30 сая
414.70 сая
555.60 сая
562.20 сая
Gain or loss from assets sale
-
-33.90 сая
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google аппс